24P Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
نویسندگان
چکیده
Intermediate biopsies during neoadjuvant treatment might offer opportunities for prediction of pathological complete response (pCR) and patient outcome, which could be a basis de-escalation treatment. However, their relevance clinical decisions is not clear. We evaluated intermediate that were taken from 297 patients with invasive breast cancer three prospective, randomized trials (GeparQuattro, -Quinto, -Sixto). the presence cancer, tumor-infiltrating lymphocytes (TILs) Ki-67 expression compared results to pre-treatment samples. explored association residual in as well dynamics TILs pCR rates disease-free survival. Of tumors, 87 (29%) samples triple-negative (TNBC), 138 (46%) HR+/HER2- 72 (24%) HER2+. found tumor cells 70% biopsies, significant differences between subtypes (HR+/HER2-: 84%; TNBC: 62%, HER2+: 51%; p<0.001). In cohort, 8% achieved after completion (pCR rate tumor: 19%, HR+/HER2: 3%; 11%). If no was present, 50% cohort (TNBC: 48%, HR+/HER2-: 27%; 66%). An increase baseline biopsy associated higher probability overall study (p=0.001). A similar or increased low (p=0.004) shorter survival TNBC (p=0.04). can identify are unlikely achieve therapy. After further validation, this may useful adaptation For translational biomarker research, tool mechanisms therapy resistance discovery. Additional studies will needed demonstrate if standardized sampling procedures improve through biopsies.
منابع مشابه
Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study
Background & Objective: Premalignant lesions of cervix have increased dramatically in recent years. Early diagnosis and management of abnormalitie...
متن کاملOutcome after neoadjuvant chemotherapy in Asian breast cancer patients
We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invas...
متن کاملRethinking neoadjuvant chemotherapy for breast cancer.
Jayant S Vaidya professor of surgery and oncology and consultant breast cancer surgeon 1 , Samuele Massarut director of oncological breast surgery , Hrisheekesh J Vaidya medical student , Emma C Alexander medical student , Thomas Richards consultant in clinical oncology , Jochem A Caris senior breast surgery registrar 7 , Bhawna Sirohi consultant medical oncologist , Jeffrey S Tobias professor ...
متن کاملNeoadjuvant chemotherapy for operable breast cancer.
Adjuvant systemic chemotherapy has been shown to prolong survival in all subsets of patients with breast cancer. In addition, among patients with locally advanced breast cancer, neoadjuvant orpreoperative chemotherapy has improved the ability to perform breast-conserving therapy. This observation, combined with multiple preclinical hypotheses and the results of laboratory studies, has prompted ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.03.039